Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Expenses (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Accumulated Expenses for 7 consecutive years, with $9.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 5.06% to $9.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.1 million, a 5.06% decrease, with the full-year FY2024 number at $8.1 million, down 0.53% from a year prior.
  • Accumulated Expenses was $9.1 million for Q3 2025 at 4D Molecular Therapeutics, up from $918000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $16.2 million in Q1 2025 to a low of $918000.0 in Q2 2025.
  • A 5-year average of $6.2 million and a median of $5.5 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 158.77% in 2024, then crashed 83.29% in 2025.
  • 4D Molecular Therapeutics' Accumulated Expenses stood at $4.0 million in 2021, then surged by 42.44% to $5.7 million in 2022, then soared by 43.24% to $8.1 million in 2023, then fell by 0.53% to $8.1 million in 2024, then grew by 12.51% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Accumulated Expenses are $9.1 million (Q3 2025), $918000.0 (Q2 2025), and $16.2 million (Q1 2025).